Deutsche Bank AG Makes New $3.01 Million Investment in Harrow, Inc. $HROW

Key Points

• Deutsche Bank acquired 70,862 Harrow shares worth approximately $3.01 million in the second quarter, representing about 0.19% of the company. Institutional investors collectively own 72.76% of Harrow.
• Harrow reported quarterly revenue of $70.66 million, slightly above estimates, but its loss of $0.46 per share significantly missed the expected $0.18 loss. The company posted a negative net margin of 13.51% and negative return on equity of 38%.
• Analyst sentiment remains mixed but leans positive, with a consensus “Moderate Buy” rating and a $69.43 price target versus the stock’s reported price of $39.33. Shares recently traded between a 52-week low of $28.54 and high of $54.85.

Deutsche Bank AG purchased a new stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 70,862 shares of the company's stock, valued at approximately $3,010,000. Deutsche Bank AG owned approximately 0.19% of Harrow at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in HROW. University of Texas Texas AM Investment Management Co. purchased a new position in Harrow during the fourth quarter worth about $26,000. KBC Group NV purchased a new position in shares of Harrow during the first quarter worth about $31,000. Raymond James Financial Inc. bought a new position in shares of Harrow in the second quarter worth approximately $48,000. SBI Securities Co. Ltd. increased its position in shares of Harrow by 393.5% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company's stock worth $52,000 after purchasing an additional 846 shares during the last quarter. Finally, State of Wyoming purchased a new stake in Harrow in the second quarter valued at approximately $72,000. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Price Performance

Shares of NASDAQ:HROW opened at $39.33 on Thursday. The company has a quick ratio of 2.08, a current ratio of 2.24 and a debt-to-equity ratio of 19.70. The stock has a market cap of $1.47 billion, a PE ratio of -39.33 and a beta of 0.28. The company's fifty day moving average is $41.48 and its 200 day moving average is $39.65. Harrow, Inc. has a 52 week low of $28.54 and a 52 week high of $54.85.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.28). The business had revenue of $70.66 million for the quarter, compared to analysts' expectations of $70.35 million. Harrow had a negative net margin of 13.51% and a negative return on equity of 38.00%.

Insiders Place Their Bets

In related news, insider Amir Shojaei sold 11,250 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $40.00, for a total transaction of $450,000.00. Following the transaction, the insider directly owned 11,250 shares in the company, valued at $450,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 12.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on HROW shares. Weiss Ratings reissued a "sell (e+)" rating on shares of Harrow in a research note on Monday, July 20th. Cantor Fitzgerald dropped their price objective on shares of Harrow from $91.00 to $88.00 and set an "overweight" rating for the company in a report on Wednesday, May 13th. Zacks Research cut Harrow from a "hold" rating to a "strong sell" rating in a research note on Tuesday, August 11th. BTIG Research restated a "buy" rating and set a $63.00 price target on shares of Harrow in a research report on Tuesday, August 11th. Finally, Wall Street Zen raised Harrow from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $69.43.

Harrow Profile

Harrow Health, Inc NASDAQ: HROW is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.

Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow, Inc. (NASDAQ:HROW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.